What is nagalase?
Yamamoto (1997, 2008b) and others (Mohamad 2002) suggested nagalase as a basis for the use of GcMAF and for the monitoring of treatment success. Nagalase is one of the body’s essential enzymes, which is involved in the catabolism of glycan. Nagalase can transfer GcMAF into an inactive form that can no longer be used by the immune system as a signal substance. Yamamoto argues that tumors release increased amounts of nagalase in order to weaken the immune system. An increase amount of nagalase is therefore linked with tumors and tumor growth. It is undisputed that tumors can diminish the efficacy of the immune system. On the other hand, there are no reference levels for nagalase in literature which could, for example, designate the reference levels in tumor-free people. Scientists only know that very low measured levels of nagalase indicate Schindler’s disease, a degenerative illness of the nervous system.
In our opinion, nagalase is well-suited in regard to tumors as a relative course marker. That is to say, several values must be measured in chronologically defined intervals. The influence of therapeutic agents or signal substances on tumors can be determined this way.
It should always be remembered that nagalase is an enzyme that is essential to the body’s functions. This enzyme is formed independent of tumors in the body in varying amounts as needed. Markers like uPAR and others have proven meaningful in our work, and reduction of the baseline value after the use of GcMAF could to be determined (Fennon et al. 2010; Smith et al. 2010). It became apparent that increased expression of uPAR can be observed in several malignant tumors, which use the uPAR/plasminogen system also to form their metastases.